WASHINGTON, Oct 16 (Reuters) - U.S. President Donald

Trump said on Thursday that the price of Novo Nordisk's

best-selling weight-loss drug would be lowered and

that negotiations over price changes would be swift.

Trump made the comments during a White House event on

fertility treatments and drug pricing. He was asked by reporters

to identify the name of a drug that he earlier in the event said

would be made less expensive.

"I was referring to Ozempic, or - I was referring to - the

fat loss drug?.... They'll be much lower," Trump said.

Novo sells Ozempic for managing diabetes while Wegovy is

approved for weight-loss. Both drugs contain the same active

ingredient, semaglutide.

Asked for comment, a Novo spokesperson said: "Novo Nordisk

has engaged in discussions with the Administration regarding the

Most Favored Nation executive order." The spokesperson said the

company was focused on improving patient access and

affordability, but did not comment directly on Trump's remarks.

Trump earlier said that under his administration's plans,

the price of the drug would be reduced to $150 from $1,300.

Ozempic has a list price of about $1,000 for a month's supply

but is sold directly by Novo to cash-pay customers for $499 per

month.

During the same White House event, Dr. Mehmet Oz, who runs

the Centers for Medicare and Medicaid Services, said that the

agency had not yet finished negotiating the price for GLP-1

drugs, which are used to treat diabetes and obesity.

Novo's Ozempic is one of the drugs that the agency has

chosen for price negotiations.